* WAVE Life Sciences Ltd WVE.OQ WVE.O is expected
to show a
rise in quarterly revenue when it reports results on May 9 for
the period ending March 31 2024
* The Singapore-based company is expected to report a
77.5% increase in revenue to $22.946 million from $12.93 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for WAVE Life Sciences Ltd
is for
a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for WAVE Life
Sciences Ltd is $13.50, above its last closing price of $5.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.13 -0.23 -0.15 Beat 33.8
Sep. 30 2023 -0.11 -0.18 0.07 Beat 139.3
Jun. 30 2023 -0.32 -0.33 -0.20 Beat 39.7
Mar. 31 2023 -0.17 -0.04 -0.27 Missed -575
Dec. -0.47 -0.41 -0.47 Missed -14.6
31 2022
Sep. 30 2022 -0.50 -0.50 -0.42 Beat 15.4
Jun. 30 2022 -0.54 -0.54 -0.62 Missed -14
Mar. 31 2022 -0.55 -0.55 -0.62 Missed -11.7
This summary was machine generated May 7 at 15:58 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)